Invuity, Inc. (NASDAQ:IVTY) – Investment analysts at Leerink Swann cut their Q4 2017 earnings per share (EPS) estimates for Invuity in a research note issued on Tuesday. Leerink Swann analyst R. Newitter now forecasts that the medical instruments supplier will post earnings per share of ($0.50) for the quarter, down from their prior forecast of ($0.49). Leerink Swann also issued estimates for Invuity’s Q4 2018 earnings at ($0.53) EPS, FY2018 earnings at ($1.91) EPS and FY2019 earnings at ($1.40) EPS.
A number of other equities research analysts also recently commented on the company. Piper Jaffray Companies reaffirmed a “buy” rating and set a $12.00 target price on shares of Invuity in a report on Friday. Zacks Investment Research upgraded Invuity from a “sell” rating to a “hold” rating in a research report on Wednesday, October 4th. Northland Securities reiterated a “buy” rating and set a $13.00 price target on shares of Invuity in a research report on Tuesday, September 26th. Finally, ValuEngine upgraded Invuity from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $11.67.
Shares of Invuity (NASDAQ IVTY) opened at $8.45 on Friday. The company has a debt-to-equity ratio of 5.39, a quick ratio of 2.63 and a current ratio of 2.90. Invuity has a twelve month low of $5.70 and a twelve month high of $9.70.
Invuity (NASDAQ:IVTY) last released its earnings results on Tuesday, November 7th. The medical instruments supplier reported ($0.52) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.56) by $0.04. Invuity had a negative return on equity of 212.38% and a negative net margin of 111.43%. The firm had revenue of $9.60 million during the quarter, compared to the consensus estimate of $9.87 million.
Institutional investors have recently bought and sold shares of the company. CAPROCK Group Inc. increased its position in shares of Invuity by 28.6% in the third quarter. CAPROCK Group Inc. now owns 45,000 shares of the medical instruments supplier’s stock valued at $401,000 after buying an additional 10,000 shares in the last quarter. OxFORD Asset Management LLP purchased a new stake in shares of Invuity in the second quarter valued at approximately $374,000. B. Riley Financial Inc. purchased a new stake in shares of Invuity during the second quarter worth approximately $3,625,000. Royce & Associates LP increased its position in shares of Invuity by 141.9% during the second quarter. Royce & Associates LP now owns 98,939 shares of the medical instruments supplier’s stock worth $717,000 after purchasing an additional 58,033 shares in the last quarter. Finally, FMR LLC increased its position in shares of Invuity by 0.5% during the first quarter. FMR LLC now owns 829,564 shares of the medical instruments supplier’s stock worth $6,595,000 after purchasing an additional 4,264 shares in the last quarter. Institutional investors and hedge funds own 66.01% of the company’s stock.
Invuity, Inc, a medical technology company, develops various surgical devices to address various surgical procedures in the United States. The company integrates its intelligent photonics technology platform into its single-use and reusable advanced surgical devices to address various critical intracavity illumination and visualization challenges.
Receive News & Ratings for Invuity Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invuity Inc. and related companies with MarketBeat.com's FREE daily email newsletter.